These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6765 related articles for article (PubMed ID: 24660121)
41. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539 [TBL] [Abstract][Full Text] [Related]
42. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Koya RC; Mok S; Otte N; Blacketor KJ; Comin-Anduix B; Tumeh PC; Minasyan A; Graham NA; Graeber TG; Chodon T; Ribas A Cancer Res; 2012 Aug; 72(16):3928-37. PubMed ID: 22693252 [TBL] [Abstract][Full Text] [Related]
43. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454 [TBL] [Abstract][Full Text] [Related]
44. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328 [TBL] [Abstract][Full Text] [Related]
45. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance. Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222 [TBL] [Abstract][Full Text] [Related]
46. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Tian Y; Guo W Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491 [TBL] [Abstract][Full Text] [Related]
47. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Jazirehi AR; Baritaki S; Koya RC; Bonavida B; Economou JS Cancer Res; 2011 Feb; 71(4):1406-17. PubMed ID: 21159666 [TBL] [Abstract][Full Text] [Related]
48. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954 [TBL] [Abstract][Full Text] [Related]
49. Targeting CDC7 sensitizes resistance melanoma cells to BRAF Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454 [TBL] [Abstract][Full Text] [Related]
50. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057 [TBL] [Abstract][Full Text] [Related]
51. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
53. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724 [TBL] [Abstract][Full Text] [Related]
54. An alternative pathway for cellular protection in BRAF inhibitor resistance in aggressive melanoma type skin cancer. Mei XL; Wei FL; Jia LL; Ji YZ Chem Biol Interact; 2020 May; 323():109061. PubMed ID: 32194039 [TBL] [Abstract][Full Text] [Related]
55. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467 [TBL] [Abstract][Full Text] [Related]
56. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116 [TBL] [Abstract][Full Text] [Related]
57. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Boni A; Cogdill AP; Dang P; Udayakumar D; Njauw CN; Sloss CM; Ferrone CR; Flaherty KT; Lawrence DP; Fisher DE; Tsao H; Wargo JA Cancer Res; 2010 Jul; 70(13):5213-9. PubMed ID: 20551059 [TBL] [Abstract][Full Text] [Related]
58. BRAF Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175 [TBL] [Abstract][Full Text] [Related]